The American Society of Hematology and ASH Research Collaborative stand in unity with the Council of Medicine Specialty Societies (CMSS) and the 800,000 physicians across 45 medical specialties that deplore the negative impact of racism in our nation and of racial inequities in our healthcare system.
The ASH Research Collaborative (ASH RC) COVID-19 Registry for Hematologic Malignancy has reached the critical milestone of surpassing its first 100 clinical cases submitted.
ASH Clinical News recently covered the launch of the ASH RC Data Hub COVID-19 Registry.
The Data Hub’s Oversight Group Chair, Dr. William Wood, was recently interviewed by the ASCO Post about the ASH RC Data Hub COVID-19 Registry for Hematologic Malignancy.
The Center for Health Information Partnerships (CHIP), the ASH Research Collaborative (ASH RC), and Prometheus Research have collaborated to develop a “communicator” between two nationwide health data standards.
The ASH Research Collaborative’s Data Hub COVID-19 Registry for Hematologic Malignancy was recently covered in Healio.
A global registry for COVID-19 cases.
Dr. William Wood provided an update on the ASH Research Collaborative Data Hub in a recent issue of the Hematologist.
The ASH Research Collaborative (ASH RC) has collaborated with two industry leaders, Novartis Pharmaceuticals Corporation (Novartis) and Amgen, to include de-identified patient data from three separate studies of nearly 500 patients living with Sickle Cell Disease (SCD) and more than 1,000 patients with multiple myeloma as part of an unprecedented data sharing initiative.
The ASH Research Collaborative’s Sickle Cell Disease (SCD) Clinical Trials Network (CTN) patient-centered approach was recently featured in Media Planet’s Clinical Trials issue.
